International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 65-73
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |
The Effect of Temozolomide as Consolidation Chemotherapy on Treatment Results of Glioblastoma Multiforme Patients Treated with Concomittant Radiotherapy and Temozolomide
Celalettin EROĞLU1, Serdar SOYUER1, Oğuz G. YILDIZ1, Okan ORHAN1, Bünyamin KAPLAN1, Metin ÖZKAN2, Ahmet MENKÜ3
1Erciyes Üniversitesi, Tıp Fakültesi, Radyasyon Onkolojisi Anabilim Dalı
2Erciyes Üniversitesi, Tıp Fakültesi, Medikal Onkoloji Bilim Dalı
3Erciyes Üniversitesi, Tıp Fakültesi, Nöroşirurji Anabilim Dalı, KAYSERİ
Keywords: Glioblastome multiforme, Temozolomide, Concomittant radiotherapy
This retrospective study was performed to determine the efficacy of adjuvant temozolomide after radiotherapy withconcomitant temozolomide in patients with newly diagnosed glioblastome multiforme.
Twenty-nine patients (15 in arm I and 14 in arm II) were included in this retrospective trial. Temozolomide (75 mg/m2/d x 7 d/wk for 6 weeks) was administered concomitantly with fractionated radiotherapy (60 Gy total dose: 2 Gy x 5 d/wk for 6 weeks) followed by adjuvant temozolomide monotherapy (200 g/m2/d x 5 days, every 28 days for six cycles) or no adjuvant chemotherapy.
Overall survival and median disease free survival were 19.4 and 7 months respectively in arm I. Overall survival and median disease free survival were 20.9 and 6 months respectively in arm II. There was no statistical significance (p=0.37 ve p=0.06 respectively).
We could not determine any benefit of adjuvant temozolomide following concurrent temozolomide with radiotherapy in this limited number retrospective cohort. Further studies are needed in order to clarify this issue.
Celalettin EROĞLU1, Serdar SOYUER1, Oğuz G. YILDIZ1, Okan ORHAN1, Bünyamin KAPLAN1, Metin ÖZKAN2, Ahmet MENKÜ3
1Erciyes Üniversitesi, Tıp Fakültesi, Radyasyon Onkolojisi Anabilim Dalı
2Erciyes Üniversitesi, Tıp Fakültesi, Medikal Onkoloji Bilim Dalı
3Erciyes Üniversitesi, Tıp Fakültesi, Nöroşirurji Anabilim Dalı, KAYSERİ
Keywords: Glioblastome multiforme, Temozolomide, Concomittant radiotherapy
This retrospective study was performed to determine the efficacy of adjuvant temozolomide after radiotherapy withconcomitant temozolomide in patients with newly diagnosed glioblastome multiforme.
Twenty-nine patients (15 in arm I and 14 in arm II) were included in this retrospective trial. Temozolomide (75 mg/m2/d x 7 d/wk for 6 weeks) was administered concomitantly with fractionated radiotherapy (60 Gy total dose: 2 Gy x 5 d/wk for 6 weeks) followed by adjuvant temozolomide monotherapy (200 g/m2/d x 5 days, every 28 days for six cycles) or no adjuvant chemotherapy.
Overall survival and median disease free survival were 19.4 and 7 months respectively in arm I. Overall survival and median disease free survival were 20.9 and 6 months respectively in arm II. There was no statistical significance (p=0.37 ve p=0.06 respectively).
We could not determine any benefit of adjuvant temozolomide following concurrent temozolomide with radiotherapy in this limited number retrospective cohort. Further studies are needed in order to clarify this issue.
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |